Search

Your search keyword '"Forconi, Francesco"' showing total 1,036 results

Search Constraints

Start Over You searched for: Author "Forconi, Francesco" Remove constraint Author: "Forconi, Francesco"
1,036 results on '"Forconi, Francesco"'

Search Results

201. BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia

203. Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

204. The variable regulatory B10 capacity of Chronic Lymphocytic Leukemias associates with B-cell receptor anergy and epigenetic programming

206. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia

207. Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications

209. Surface IgM Levels Independently Influence Clinical Behavior and Associate with Altered Phenotype and Genetics in Chronic Lymphocytic Leukemia

211. The Dual PI3K/mTOR Inhibitor PF-04691502 Induces Substantial Apoptosis in Chronic Lymphocytic Leukemia Cells in Vitro and Prolongs Survival in the Eµ-TCL1 Mouse Model

212. A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia

214. Author response: Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia

216. Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor

217. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia

220. Genome-Wide Promoter Methylation Of Hairy Cell Leukemia (HCL)

222. Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes

224. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ fromde novodiffuse large B-cell lymphoma

225. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

227. In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia

228. Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia

229. Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH

231. MGA, a suppressor ofMYC, is recurrently inactivated in high risk chronic lymphocytic leukemia

232. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone

233. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome

234. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

235. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

236. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

237. BTKand PLCG2remain unmutated in one third of patients with CLL relapsing on ibrutinib

238. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness

239. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array

240. Mutations of NOTCH1 Are An Independent Predictor of Survival in Chronic Lymphocytic Leukemia

241. Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway

243. Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment

244. Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia

246. SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS)

247. A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients

248. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

249. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis

250. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia

Catalog

Books, media, physical & digital resources